About Hyris
Hyris is a company based in London (United Kingdom) founded in 2014. Hyris has raised $2.84 million across 2 funding rounds from investors including Indena, Astanor and NEOS Medica. Hyris offers products and services including Hyris System™, qPCR Devices, and AI Software. Hyris operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter London, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hyris Limited
- Date of Incorporation 05 Nov, 2014
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.84 M (USD)
in 2 rounds
-
Latest Funding Round
$2.84 M (USD), Series A
Jun 09, 2020
-
Investors
Indena
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hyris
Hyris offers a comprehensive portfolio of products and services, including Hyris System™, qPCR Devices, and AI Software.
Multi-market platform for genetic testing and marketplace transactions
Miniaturized devices for superior genetic analysis performance
Cloud-based platform for operating and gaining testing insights
People of Hyris
Unlock access to complete
Funding Insights of Hyris
Hyris has successfully raised a total of $2.84M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.84 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hyris
Hyris has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Indena, Astanor and NEOS Medica.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Astanor is focused on transforming the agrifood system through investments.
|
Locked | Locked | Locked | |
|
Early-stage AI startups are funded and supported by Pi Campus.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Hyris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hyris
Investment portfolio details for Hyris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hyris
Detailed financials for Hyris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hyris Comparisons
Peer comparison for Hyris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hyris
Hyris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
Detailed competitors of Hyris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hyris
Complete news archive for Hyris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hyris
Hyris was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Hyris is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Stefano Lo Priore is the current CEO of Hyris.
Hyris is a funded company, having raised a total of $2.84M across 2 funding rounds to date.
Hyris was founded in 2014 in London, United Kingdom. An integrated platform for genetic testing of biological samples has been developed, featuring the compact bCUBE 2.0 for data analysis. Real-time results are recorded on the cloud-based Hyris bAPP, which controls the platform for Real-Time PCR and isothermal protocols. Services are extended to the medical, veterinary, and agrofood sectors through this technology.
Hyris's top competitors include Qiagen, Parse Biosciences and NuProbe.
Hyris offers Hyris System™, qPCR Devices, and AI Software.
Hyris has 5 investors. Key investors include Indena, Astanor, NEOS Medica, Pi Campus, and UniCredit Start Lab.